Controversies in radioiodine therapy: Relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres

European Journal of Endocrinology

Volumn 147, Issue 1, 2002, Pages 1-11

  Bonnema, S J ^a   Bartalena, L ^a   Toft, A D ^a   Hegedus L ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; GLUCOCORTICOID; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; METHYLTHIOURACIL; PREDNISONE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOPROTECTIVE AGENT; RECOMBINANT THYROTROPIN; THIAMAZOLE; THIOL DERIVATIVE; THIONAMIDE; THIOUREA; THYROID ANTIBODY; THYROID HORMONE; THYROID PEROXIDASE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY;

ANTIBODY BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; GOITER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HYPERTHYROIDISM; INSPIRATORY CAPACITY; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; ORGAN SIZE; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION PROTECTION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIDE EFFECT; THYROID DISEASE; THYROIDECTOMY; TRACHEA COMPRESSION; TREATMENT OUTCOME;

EID: 0036319536     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1470001     Document Type: Review

References (93)

1. The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey
2. Current trends in the management of Graves' disease
3. Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey
4. Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey
5. Management of the solitary thyroid nodule: A North American survey
6. Management of the nontoxic multinodular goitre: A European questionnaire study
7. Management of the nontoxic multinodular goiter: A North American survey
8. Studies on the occurrence of ophthalmopathy in Graves' disease
9. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism
10. Management of Graves' ophthalmopathy: Reality and perspectives
11. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: A case-control study
12. Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy
13. Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but..
14. Radioiodine therapy and Graves' opthalmopathy
15. Ten year results of 1-131 therapy in hyperthyroidism
16. The endocrine eye lesion in hyperthyroidism
17. Large doses of radioiodine in Graves' disease: Effects on ophthalmopathy and long-acting thyroid stimulator
18. Studies on the pathogenesis of the ophthalmopathy of Graves' disease
19. Studies of serum long-acting thyroid stimulator (LATS) in relation to exophthalmos after therapy for thyrotoxicosis
20. Identification of a subgroup of Graves' disease patients at higher risk for severe ophthalmopathy after radioiodine
21. Graves' ophthalmopathy after subtotal thyroidectomy and radioiodine therapy
22. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: Prognostic factors and the role of methimazole
23. Malignant exophthalmos after iodine-131 treatment
24. Treatment of Graves' disease and the course of ophthalmopathy
25. Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves' disease
26. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism
27. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism
28. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism
29. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy
30. Influencia del tratamento del hipertiroidismo en el curso del exoftalmos
31. Sequential changes in serum thyroid peroxidase following radioiodine therapy of patients with differentiated thyroid carcinoma
32. Changes in thyroid-stimulating immunoglobulins during antithyroid therapy
33. Peripheral blood T cell activation after radioiodine treatment for Graves' disease
34. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease
35. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy
36. Importance of TSH receptor activation in the development of severe endocrine ophthalmopathy
37. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?
38. Treating severe Graves' ophthalmopathy
39. Preventing Graves' ophthalmopathy
40. Acute changes in thyroid function in patients treated with radioactive iodine
41. 131I ablation for Graves' disease
42. Thyroidal triiodothyronine and thyroxine in Graves' disease: Correlation with presurgical treatment, thyroid status and iodine content
43. Radiotherapeusis
44. Reduction in lethal effect of X-radiation by pretreatment with thiourea or sodium ethane dithiophosphonate
45. On the possibility of protecting the living organism against roentgen rays by chemical means
46. 131I therapy
47. Antithyroid drugs in iodine-131 therapy of hyperthyroidism
48. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease
49. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease
50. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism
51. Effect of pretreatment with carbimazole in patients with thyrotoxicosis subsequently treated with radioactive iodine
52. The effect of methimazole pretreatment on the efficacy of radioiodine therapy in Graves' hyperthyroidism: One-year follow-up of a prospective, randomized study
53. Success rate of radioiodine therapy in Graves' disease; the influence of thyrostatic medication
54. Treatment of hyperthyroidism with radioiodine: Adjunctive therapy with antithyroid drugs reconsidered
55. Clinical pharmacokinetics of anti-thyroid drugs
56. 35S-antithyroid drugs by the thyroid gland
57. Intrathyroidal concentrations of methimazole in patients with Graves' disease
58. Experience in a specialist thyroid surgery unit: A demographic study, surgical complications, and outcome
59. The use of fine-needle aspiration biopsy under ultrasound guidance to assess the risk of malignancy in patients with a multi-nodular goiter
60. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer
61. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter
62. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre
63. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified?
64. High long term recurrence rate after subtotal thyroidectomy for nodular goitre
65. Observer variation in the clinical assessment of the thyroid gland
66. Accuracy of the clinical assessment of thyroid size
67. MR imaging of large multinodular goiters: Observer agreement on volume versus observer disagreement on dimensions of the involved trachea
68. Magnetic resonance imaging for volume estimation of large multinodular goitres: A comparison with scintigraphy
69. Iodine-131 therapy in sporadic nontoxic goiter
70. Radioiodine therapy for multinodular toxic goiter
71. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre
72. Radioiodine treatment of multinodular non-toxic goitre
73. 131I therapy in patients with non-toxic multinodular goiter
74. Treatment of non-toxic multinodular goiter with radioactive iodine
75. Diagnosis and management of large toxic multinodular goiters
76. Radioiodine therapy in voluminous multinodular non-toxic goitre
77. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: Effect on thyroid function and size and pulmonary function
78. Large, compressive goiters treated with radioiodine
79. Radioiodine for nontoxic multinodular goiter
80. Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging
81. Acute changes in thyroid volume and function following 131I therapy of multinodular goitre
82. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre
83. Outpatient management of patients with large multi-nodular goitres treated with fractionated radioiodine
84. Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement
85. 131I-treatment of multinodular nontoxic goiter evaluated by flow volume loop curves
86. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease
87. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodine uptake in nontoxic nodular goiter
88. 131I treatment in patients with nontoxic goiter
89. 131I treatment of non-toxic goiter
90. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: A population-based cohort study
91. Cancer mortality following treatment for adult hyperthyroidism
92. Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism
93. Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters